PhaseBio Pharmaceuticals Inc expected to post a loss of 31  cents a share - Earnings Preview

PhaseBio Pharmaceuticals

08/08/2022 19:31

* PhaseBio Pharmaceuticals Inc  PHAS.OQ   PHAS.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 10 (estimated). 
    * The Malvern Pennsylvania-based  company is expected to
report  a
91.9% decrease in revenue to $833.33 thousand from $10.34
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for PhaseBio
Pharmaceuticals
Inc is for a loss of 31 cents per share. For the same quarter
last year, the company reported a loss of 60 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $15​, above​ its last closing price
of $1.26. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.67       -0.66      -0.23     Beat    65.4
 Dec. 31 2022  -0.52       -0.59      -0.90     Missed  -53.6
 Sep. 30 2021  -0.63       -0.61      -0.66     Missed  -8.9​
 Jun. 30 2021  -0.09       -0.46      -0.60     Missed  -30.4
 ​​Mar.        -0.73       -0.73      -0.87     Missed  -18.6
 31 2021                                                
 Dec. 31 2020  -0.67       -0.70      -1.03     Missed  -46.1​
 Sep. 30 2020  -0.78       -0.77      -0.86     Missed  -12.1
 Jun. 30 2020  -0.53       -0.52      -0.98     Missed  -88.5
 This summary was machine generated August 8 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated